Despite this success, CTLA-4 mAb still faces numerous challenges, including: (1) The excessive molecular weight (160–170 kD) limits the penetration of mAb into tumor microenvironment and the crossing of the blood-brain barrier. The gene discussed is CTLA4; the disease is neoplasm.